Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Evommune, Inc. (EVMN)
Company Research
Source: Business Wire
– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD)– EVO756 on track to report Phase 2b top-line data in chronic spontaneous urticaria (CSU) and AD in 2Q26 and 2H26, respectively– Strengthened balance sheet with $125 million private placement to support additional clinical milestones and extend runway through 2028 PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.“The positive top-line Phase 2a data for EVO301 marks an important milestone for Evommune and further validates IL-18 inhibition as a compelling approach for patients living with AD. We look forward to advancing the program forward and exploring an optimal
Show less
Read more
Impact Snapshot
Event Time:
EVMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVMN alerts
High impacting Evommune, Inc. news events
Weekly update
A roundup of the hottest topics
EVMN
News
- Evommune, Inc. GAAP EPS of -$11.22, revenue of $13M [Seeking Alpha]Seeking Alpha
- Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]Yahoo! Finance
- Evommune (NYSE:EVMN) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Evommune Announces $125 Million Private PlacementBusiness Wire
- Evommune (NYSE:EVMN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.MarketBeat
EVMN
Sec Filings
- 3/5/26 - Form S-8
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- EVMN's page on the SEC website